牙周炎分期分级影响阿莫西林/甲硝唑全身辅助治疗的临床获益
本文为ABPARO试验的探索性亚组分析,按2018年牙周炎分期分级重新评估全身阿莫西林/甲硝唑辅助龈下刮治的疗效。结果显示在广泛型III期和C级患者中,联合用药组疾病进展位点百分比显著低于安慰剂组,而局限型III期和B级未见显著差异。
要点
- 广泛型III期和C级牙周炎患者可从全身阿莫西林/甲硝唑辅助治疗中获益。
- 局限型III期和B级患者联合用药与安慰剂无显著差异。
- 治疗决策应结合牙周炎分期分级进行个体化选择。
核心结论
- 在广泛型III期和C级牙周炎中,全身阿莫西林/甲硝唑辅助龈下刮治较安慰剂显著降低疾病进展位点百分比。
- 局限型III期和B级患者中未观察到显著治疗差异。
研究设计与样本
- 按2018年牙周炎分类重新分期(局限型III期49例、广泛型III期206例、IV期150例)和分级(因缺失X线片仅222例分级:B级73例、C级149例)。
主要发现
- 主要结局为基线/随机化后27.5个月时每患者新附着丧失≥1.3mm的位点百分比(PSAL≥1.3mm)。
- 广泛型III期:安慰剂组中位数8.0%(四分位距4.5/14.3%)vs 联合用药组4.7%(2.4/9.0%),p<.001。
- IV期:安慰剂组8.5%(5.1/14.4%)vs 联合用药组5.7%(3.3/10.6%),p=.008。
- C级:安慰剂组9.4%(5.3/14.3%)vs 联合用药组4.8%(2.5/9.4%),p<.001。
- 局限型III期(p=.749)和B级(p=.151)无显著差异。
关键数值与推荐
- 广泛型III期和C级患者中,联合用药组PSAL≥1.3mm位点百分比显著低于安慰剂组(广泛型III期p<.001,C级p<.001)。
- 局限型III期和B级患者中,联合用药与安慰剂无显著差异(p=.749和p=.151)。
临床怎么用
- 对广泛型III期或C级牙周炎患者,可考虑在龈下刮治基础上辅助全身阿莫西林/甲硝唑以降低疾病进展风险。
- 对局限型III期或B级患者,不应常规辅助全身抗生素,需个体化评估。
局限性
- 为探索性亚组分析,分级分析因缺失X线片仅纳入222例患者。
- 结果需进一步验证,不能直接推广至所有牙周炎患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Assessment of treatment response after systemic amoxicillin/metronidazole adjunctive to subgingival instrumentation (SI) according to stages and grades of the 2018 classification of periodontal diseases. MATERIALS AND METHODS: We carried out exploratory re-analysis of the placebo-controlled, multi-centre ABPARO trial (52; 45/60 years of age; 205 males, 114 active smokers). Patients were randomized to SI with systemic amoxicillin 500 mg/metronidazole 400 mg (three times a day for 7 days, n = 205; ANTI) or placebo (n = 200; PLAC) and maintenance therapy every 3 months. Patients were reclassified according to the 2018 classification (stage/extent/grade). Treatment effect was the percentage of sites per patient with new attachment loss ≥1.3 mm (PSAL ≥ 1.3 mm) at 27.5 months post-baseline/randomization. RESULTS: All patients were assigned according to the stage (n = 49 localized stage III, n = 206 generalized stage III, n = 150 stage IV). Because of missing radiographs, only 222 patients were assigned to grades (n = 73 B, n = 149 C). Treatment (PLAC/ANTI) resulted in PSAL ≥ 1.3 mm (median; lower/upper quartile) in localized stage III (PLAC: 5.7; 3.3/8.4% vs. ANTI: 4.9; 3.0/8.3%; p = .749), generalized stage III (8.0; 4.5/14.3% vs. 4.7; 2.4/9.0%; p < .001), stage IV (8.5; 5.1/14.4% vs. 5.7; 3.3/10.6%; p = .008), grade B (4.4; 2.4/6.7% vs. 3.6; 1.9/4.7%; p = .151) and grade C (9.4; 5.3/14.3% vs. 4.8; 2.5/9.4%; p < .001). CONCLUSIONS: In generalized periodontitis stage III/grade C, a clinically relevant lower percentage of disease progression after adjunctive systemic amoxicillin/metronidazole was observed compared to placebo (PLAC: 9.7; 5.8/14.3% vs. ANTI: 4.7; 2.4/9.0%; p < .001).
引用
- Eickholz P, Koch R, Göde M, et al. Clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis stage and grade: An exploratory sub-analysis of the ABPARO trial. J Clin Periodontol. 2023. PMID: 37293896. doi:10.1111/jcpe.13838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。